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Abstract
Background: In mid 2010, the 7-valent pneumococcal conjugate vaccine (PCV7) was replaced by the 13-valent
conjugate vaccine (PCV13) for childhood immunization in Italy. Our objective in this study was to obtain a snapshot
of pneumococcal carriage frequency, colonizing serotypes, and antibiotic resistance in healthy children in two Italian
cities one year after PCV13 was introduced.
Methods: Nasopharyngeal swabs were obtained from 571 children aged 0-5 years from November 2011-April 2012.
Pneumococcal isolates were serotyped and tested for antimicrobial susceptibility. Penicillin and/or erythromycin non-
susceptible isolates were analyzed by Multi Locus Sequence Typing (MLST).
Results: Among the children examined, 81.2% had received at least one dose of PCV7 or PCV13 and 74.9% had
completed the recommended vaccination schedule for their age. Among the latter, 57.3% of children had received
PCV7, 27.1% PCV13, and 15.6% a combination of the two vaccines. The overall carriage rate was 32.9%, with
children aged 6-35 months the most prone to pneumococcal colonization (6-23 months OR: 3.75; 95% CI: 2.19-6.43
and 24-35 months OR: 3.15, 95%CI: 2.36-4.22). A total of 184 pneumococcal isolates were serotyped and divided
into PCV7 (5.4%), PCV13 (18.0%), and non-PCV13 (82.0%) serotypes. Serotypes 6C, 24F, and 19A were the most
prevalent (10.3%, 8.6%, and 8.1%, respectively). The proportion of penicillin non-susceptible (MIC >0.6 mg/L)
isolates was 30.9%, while 42.3% were erythromycin resistant. Non-PCV13 serotypes accounted for 75.4% and
70.8% of the penicillin and erythromycin non-susceptible isolates, respectively.
Conclusions: Our results revealed low rates of PCV7 and PCV13 serotypes in Italian children, potentially due to the
effects of vaccination. As the use of PCV13 continues, its potential impact on vaccine serotypes such as 19A and
cross-reactive serotypes such as 6C will be assessed, with this study providing a baseline for further analysis of
surveillance isolates.
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Introduction
Streptococcus pneumoniae (pneumococcus) is an important
human pathogen causing a broad spectrum of infections,
ranging from upper and lower respiratory tract infections (otitis,
sinusitis, and pneumonia) to invasive pneumococcal diseases
(IPD), such as meningitis and sepsis. Children under 5 years of
age and elderly people represent high-risk groups for serious
pneumococcal infections. It was estimated in 2000 that 14.5
million children aged < 5 years were affected by a severe
pneumococcal disease, leading to about 11% of all deaths in
this age group worldwide [1].
The ecological niche of S. pneumoniae is the nasopharynx of
healthy persons, predominantly children, which represent the
main reservoir for pneumococcal transmission in the
community [2]. The rate of colonization is particularly high in
the first years of life, with pneumococci being acquired, carried
for a period of time, and then cleared in a highly dynamic
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process [3]. Nasopharyngeal colonization is a prerequisite for
developing pneumococcal disease. In a minority of colonized
persons, bacteria move from the nasopharynx to the sinuses
and middle ear cavity or to the lungs causing respiratory tract
infections, or invade the bloodstream causing systemic
infections [4]. Infection occurs based on the bacterial virulence
factors as well as the chronic or transient immune deficiency
status of the host [2]. The antiphagocytic polysaccharide
capsule is a major virulence factor and is the target of current
pneumococcal vaccines. A limited number of prevalent IPD-
causing serotypes, among the more than 90 known serotypes,
are included in pneumococcal vaccines. In 2000, a pediatric
conjugate vaccine (PCV7) containing the 7 most prevalent
serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) causing diseases
in children in North America was licensed. The widespread use
of PCV7 led to an overall decrease in IPD due to vaccine
serotypes in vaccinated children as well as non-vaccinated
persons of all ages [5,6]. Conversely, an increase in the
prevalence of non-PCV7 serotypes was documented in most
countries where the vaccine was used, both in IPD [7,8] and
carriage [9-12]. Higher-valency conjugate vaccines, PCV10
and PCV13, were subsequently formulated to extend the
serotype coverage. PCV10 included the PCV7 serotypes and
the additional serotypes 1, 5, and 7F; while, PCV13 included
the additional serotypes 1, 3, 5, 6A, 7F, and 19A.
In Italy, PCV7 was licensed in 2001 but its use was gradually
implemented in Italian regions due to different local
immunization strategies [13]. In 2008, PCV7 coverage was
55% nationally [14]. At the beginning of 2010, 14 of the 21
regions actively offered the vaccine to all infants [13], according
to the 2 + 1-dose vaccination schedule used in Italy [15].
PCV13 replaced PCV7 in all Italian regions between mid 2010
and 2011 [13]. PCV13 was administered, according to regional
immunization programs, to newborns and children who started,
but did not complete the 3 doses of PCV7; one PCV13 dose
was also recommended for children under 24 months of age
who had already received the full PCV7 vaccination series [16].
A thorough evaluation of the impact of PCV7 on the
incidence of IPD in Italy was not possible since the nationwide
surveillance program for invasive bacterial diseases began in
2007 (http://www.simi.iss.it/meningite_batterica.htm).
However, during the implementation of PCV7, a change in
the relative rates of the most common serotypes was observed,
due to a reduction of PCV7 serotypes and a concurrent
increase in non-PCV7 serotypes, most of which were included
in PCV13, such as 1, 7F, and 19A (http://www.simi.iss.it/files/
Report_MBI.pdf. Accessed 2013 May 31).
Since nasopharyngeal colonization is necessary for invasive
disease, it is critical to understand the effects of vaccines on
pneumococcal ecology. Nasopharyngeal isolates reflect strains
currently circulating in the community; therefore, changes in the
distribution of colonizing serotypes following immunization
could predict the prevalent serotypes causing IPD. Thus,
surveillance of colonization has become an important
component of the vaccination monitoring process. Recently,
Simell et al [2] suggested using pneumococcal carriage
information in vaccine trials as a marker of vaccine-induced
protection, especially in children.
Few studies regarding pneumococcal carriage have been
conducted in Italy, and most were performed prior to the
introduction of PCV7 [17,18]. These studies revealed a low
carriage rate, ranging from 8.6% to 14.9%, with PCV7
serotypes representing 56% to 63% of the isolates [17,18]. A
recent study, conducted using molecular methods in children
from Genoa in the Liguria region where PCV7 coverage was >
90%, revealed a carriage rate of 50%, with the large majority of
isolates being non-PCV7 serotypes [19].
In the present study, we examined the nasopharyngeal
carriage in children aged 0-5 years in two large Italian cities,
Bologna and Milan, at the beginning of PCV13 use. These two
cities are located in two regions of North Italy (Emilia-Romagna
and Lombardy, respectively), each with a different policy
regarding PCV7 implementation [13]. The data obtained in this
carriage study represent a picture of the serotypes circulating
in Italy one year after the introduction of PCV13 and provide a
baseline for future evaluations of the impact of PCV13.
Materials and Methods
Study design
To evaluate pneumococcal carriage in Italian children, a
cross-sectional study was conducted between November 2011
and April 2012 in children aged 0-5 years in two Italian cities,
Bologna (Emilia-Romagna region) and Milan (Lombardy
region), located in regions with different pneumococcal
vaccination policies. The Emilia-Romagna region actively
provided pneumococcal immunization to all infants since 2006;
while, the Lombardy region initially offered vaccination only to
disease-specific risk groups of children. Since 2009, Lombardy
has offered vaccination to all infants upon the parents’ or
pediatricians’ request [13]. As expected, different vaccine
coverage rates were observed in the two regions in 2008, with
95% PCV7 coverage in Emilia-Romagna and 27% in Lombardy
[14]. Vaccination coverage in Lombardy increased substantially
starting in 2009 and reached almost 80% at the time of this
study (A. Piatti, personal communication). Children attending
routine visits in the first years of life were recruited for the study
from the pediatric outpatient clinics of the S. Orsola-Malpighi
University Hospital in Bologna and a pediatric practice
associated with Hospital Maggiore Policlinico in Milan. Children
suffering from respiratory tract infections, other respiratory
problems, or chronic illnesses were excluded from the study.
A structured questionnaire was filled in by the pediatrician
and was used to collect the children’s demographic data (age,
gender, number of family members, presence of young siblings
under 6 years, daycare attendance, and presence of at least
one smoking parent) and their PCV7/PCV13 vaccination
status. Children who had received all the recommended doses
for their age, according to the Italian schedule (2+1 doses at 3,
5, and 11/13 months), or who had received a catch-up dose at
>1 year of age, were considered completely vaccinated.
Children who had not completed the recommended vaccination
schedule were classified as partially vaccinated.
Pneumococci in Young Children in the PCV13 Era
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Ethics statement
The study was approved by the Ethics Committee of S.
Orsola-Malpighi University Hospital in Bologna (reference
number: 1946/2011) and the Ethics Committee of Hospital
Maggiore Policlinico in Milan, according to the Italian
legislation. Parents or guardians of the participating children
provided written informed consent. The procedures followed
were in accordance with the European Statements for Good
Clinical Practice and the Declaration of Helsinki of the World
Medical Association.
Specimen collection
Nasopharyngeal specimens were obtained using a nylon
flocked swab (eSwab, Copan, Brescia, Italy), according to the
WHO pneumococcal colonization detection protocol [20].
Swabs were streaked onto 5% sheep blood Columbia agar
plates supplemented with 5 µg/mL gentamicin within 18 hours
of collection and were incubated overnight at 35°C in 5% CO2-
enriched air. Swabs were then stored at -80°C in milk-tryptone-
glucose-glycerol (STGG) medium (www.cdc.gov/ncidod/
biotech/files/pcr-pneumo-carriage-March2010.pdf).
Bacterial identification and serotyping
Pneumococcal isolates were detected by colony morphology
and identification was confirmed by optochin susceptibility and
bile solubility testing. Individual isolates were serotyped by
latex agglutination and the Quellung reaction using
commercially available antisera (Statens Serum Institut,
Copenhagen, Denmark).
Antimicrobial susceptibility testing and genotyping
Susceptibilities to penicillin, ceftriaxone, erythromycin,
clindamycin, tetracycline, and chloramphenicol were
determined by the antimicrobial gradient strip diffusion method
(Etest, bioMérieux, Durham, USA). The breakpoints proposed
by the EUCAST (http://www.eucast.org/clinical_breakpoints/.
Accessed 2013 May 31) were used. Briefly, for penicillin the
meningitis criteria were: susceptible, MIC ≤ 0.06 mg/L;
resistant, MIC > 0.06 mg/L. The non-meningitis criteria were:
susceptible, MIC ≤ 0.06 mg/L; resistant, MIC > 2 mg/L. For the
purpose of this study, all S. pneumoniae isolates with a
penicillin MIC > 0.06 mg/L were defined as non-susceptible.
For ceftriaxone, the breakpoints used were: susceptible, MIC ≤
0.5 mg/L; resistant, MIC > 2 mg/L. Isolates that were not
susceptible to antimicrobials were further analyzed by Multi
Locus Sequence Typing (MLST) following the procedures
described at the MLST website (http://spneumoniae.mlst.net.
Accessed 2013 Jun 20). For each serotype, complete allelic
profiles were determined for representative isolates from each
of the antibiotic susceptibility groups. Partial MLST profiles
were determined for the remaining isolates using a previously
described strategy [21]. If the xpt and ddl alleles corresponded
to those obtained for the representative isolate, the same
Sequence Type (ST) was assigned. If the xpt and ddl alleles
were divergent, a complete allelic profile was obtained. The
software eBURST, available from the MLST website, was used
to compare the STs obtained with those available at the MLST
website and to define clonal complexes (CCs). Pneumococcal
Molecular Epidemiology Network clones (PMEN website: http://
www.sph.emory.edu/PMEN/. Accessed 2013 Jun 20) were also
identified.
Statistical analysis
Data were checked for outliers, duplicate records, and
distribution of the variables. Age, computed by date of
examination minus date of birth, was analyzed as a categorical
(0-5; 6-23; 24-35; and 36-71 months) variable. For each
variable, missing values were tabulated by age, sex, categories
of outcome (colonization status), exposure (vaccination status),
and recruitment center. We examined the association between
colonization status and vaccination exposure (unvaccinated
was the reference category). Potential risk factors for
nasopharyngeal carriage of S. pneumoniae were identified by
univariate analysis. Odds ratios (ORs) and 95% confidence
intervals (CIs) for colonization were computed using logistic
random effect regression models, with the recruitment center
as the random effect. Multivariate analysis was adjusted for
other covariates like age, day-care centers attendance, number
of siblings younger than 6 years, and smoking status of
parents. The effect of potential confounding factors was
estimated by fitting a model with and without the variable of
interest and by comparing the adjusted and crude estimates.
Records with missing values for a variable were excluded for
each analysis involving that variable. Statistical analysis was
carried out in STATA 10 software (StataCorp).
Results
Study population and vaccination status
A total of 571 children, 270 from Bologna and 301 from
Milan, aged 0-5 years, were enrolled in the study. The mean
age was 35 months (SD 17.15) and 316 (55.3%) participants
were male. Overall, 78.9% (451/571) of children attended day
care centers, and this percentage was higher (97%) in the
24-71 month old group. Only 30.8% (176/571) of children had
siblings aged <6 years and 37.1% (212/571) had at least one
smoking parent. The only difference observed between the
children populations of the two cities with regard to
demographic characteristics was a higher presence of young
siblings in Milan, which was borderline significant (p= 0.051).
The vaccination status was known for 531 children: 81.2%
(431/531) had received at least one dose of PCV7 or PCV13
and 74.9% (398/531) had completed the recommended
vaccination schedule for their age. Specifically, 57.3%
(228/398) received PCV7, 27.1% (108/398) PCV13, and 15.6%
(62/398) a combination of the two vaccines. According to the
Italian schedule [16], children vaccinated with a combination of
vaccines receive 2 or 3 doses of PCV7 followed by 1 dose of
PCV13 (48/62 children, 77.4%) or 1 or 2 doses of PCV7
followed by 2 doses of PCV13 (14/62 children, 22.6%). By age-
adjusted analysis, a statistically significant difference was
found in the proportion of vaccinated children between Bologna
and Milan. In Bologna, 98.8% of children had received at least
one vaccine dose and 97.8% were completely vaccinated
Pneumococci in Young Children in the PCV13 Era
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compared with 68.1% and 57.5%, respectively, in Milan (p <
0.001).
S. pneumoniae carriage
The overall pneumococcal carriage rate was 32.9%
(188/571) and there was no significant difference between
Bologna and Milan (34.4% and 31.5%, respectively, p= 0.5).
The colonization rate increased from 7.1% in the younger age
group (0-5 months) to 33.3% (6-23 months), 33.0% (24-35
months), and 35.1% (36-71 months) in the older aged groups
(Table 1). Among colonized children, 71.8% (135/188) were
completely vaccinated with PCV7 or PCV13 or a combination
of the two, while 5.3% (10/188) were partially vaccinated.
Among the non-colonized children, 68.6% (263/383) were
completely vaccinated and 6.0% (23/383) were partially
vaccinated.
In univariate analysis, colonization was associated with age,
day-care center attendance, presence of young siblings in the
family, and prior vaccination with PCV7 (Table 1).
Unexpectedly, the presence of at least one smoking parent
was significantly associated with a lower carriage rate, both in
univariate and multivariate analyses (Table 1). Further analysis
was performed only on children from Milan, for whom
information about which parent was the smoker in the
household (if mother, father, or both) was available, and
indicated that a smoking mother was associated with a higher
risk of pneumococcal carriage in children (OR: 3.66; 95%CI:
1.53-8.73, p= 0.003). The multivariate logistic regression model
showed children 6-35 months of age were the most prone to
pneumococcal colonization (6-23 months, OR: 3.75, 95%CI:
2.19-6.43, p<0.001; 24-35 months, OR: 3.15, 95%CI:
2.36-4.22, p<0.001) (Table 1).
Serotype distribution
Overall, 189 pneumococcal isolates were obtained from 188
children, as 2 different isolates were obtained in one child. Five
isolates were not viable upon storage and could not be
serotyped. Of the 184 isolates, 31 different serotypes were
identified, with 6C (19/184, 10.3%), 24F (16/184, 8.6%), and
19A (15/184, 8.1%) being the most common; in addition, 5.4%
of the isolates (10/184) were non-typeable (NT) (Figure 1).
Overall, 5.4% of the isolates were PCV7 serotypes, 18.0%
were PCV13 serotypes, and 82.0% non-PCV13 serotypes
(Figure 1). No significant difference was observed in the
percentage of non-PCV13 serotypes between the children in
Bologna and Milan (p= 0.856). By age-adjusted multivariate
analysis, children who had received PCV7 were protected from
the included serotypes; while, children who had received
PCV13 or a combination of PCV7 and PCV13 were protected
from the serotypes included in both vaccines. Vaccination with
either PCV7 or PCV13 increased the risk of colonization with
non-PCV13 serotypes (Table 2).
Within each serotype, the orange portion indicates isolates
from Bologna and the blue portion isolates from Milan. The
arrowheads indicate PCV13 serotypes.
The ranking order of serotypes was slightly shifted between
the two populations (Table 3). In particular, the most prevalent
serotypes in Bologna were 6C, 24F, and 19A followed by 10A;
while, in Milan, serotypes 23B and 6C were the most prevalent,
followed by 11A, 15B, 24F, and 19A. In addition, some
Table 1. Univariate and multivariate analysis of risk factors for pneumococcal carriage.
 Total children (N=571) S. pneumoniae carriage Univariate Multivariate
 N (%) N (%) OR (95%CI) P OR (95%CI) P
Age-group         
0 to 5 months 28 (4.90) 2 (7.14) 1   1   
6 to 23 months 132 (23.11) 44 (33.33) 6.50 (5.44; 7.77) <0.001 3.75 (2.19; 6.43) <0.001
24 to 35 months 124 (21.71) 41 (33.06) 6.42 (4.70; 8.77) <0.001 3.15 (2.36; 4.22) <0.001
36 to 71 months 287 (50.26) 101 (35.19) 7.06 (5.85; 8.52) <0.001 3.03 (1.00; 9.21) 0.051
Day-care centres         
no 120 (21.01) 19 (15.83) 1   1   
yes 451 (78.98) 169 (37.47) 3.55 (2.77; 4.56) <0.001 2.31 (0.89; 5.98) 0.084
Young siblingsa         
0 392 (68.65) 122 (31.12) 1   1   
≥1 176 (30.82) 65 (36.93) 1.25 (1.21; 1.29) <0.001 1.20 (0.91; 1.57) 0.193
Smokinga         
no 356 (62.34) 127 (35.67) 1   1   
yes 212 (37.12) 60 (28.30) 0.71 (0.58; 0.87) 0.01 0.70 (0.61; 0.80) <0.001
Vaccination statusb         
unvaccinated 100 (17.51) 29 (29.0) 1   1   
PCV7 228 (39.93) 85 (45.21) 1.45 (1.42; 1.49) <0.001 1.34 (0.97; 1.87) 0.073
PCV7/13 + PCV13 170 (29.77) 50 (37.28) 1.02 (0.87; 1.19) 0.250 1.04 (0.74; 1.43) 0.839
partially vaccinated 33 (5.77) 10 (30.30) 1.06 (0.92; 1.22) 0.870 0.86 (0.72; 1.03) 0.121
a Data for 3 children are missing; b data for 40 children are missing
doi: 10.1371/journal.pone.0076309.t001
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serotypes were only recovered in one city, with 7F, 8, 10A,
12F, and 20 only in Bologna and 1, 6B, 18C, 29, and 34 only in
Milan (Table 3, Figure 1). With the exception of 19A, which was
the third most prevalent serotype, other PCV13 serotypes (1, 3,
6A, 6B, 7F, 14, 18C, and 19F) were poorly represented (0.5%
to 3.2%, Table 3).
Antibiotic susceptibility patterns and clonal analysis of
resistant isolates
Using the EUCAST meningitis breakpoints for penicillin (MIC
> 0.06 mg/L), 57 isolates out of 184 (30.9%) were penicillin
non-susceptible. Of these, 11 (6.0%) showed high penicillin
resistance (MIC> 1 mg/L). For the non-meningitis breakpoints,
30.4% (56/184) were intermediate to penicillin (MIC 0.12-2
mg/L), and only 1 isolate (MIC=3 mg/L) was fully resistant (MIC
> 2 mg/L). Nine isolates out of 184 (4.8%) were non-
susceptible to ceftriaxone (MIC >0.5 mg/L), 8 were
intermediate, and only 1 isolate was fully resistant (MIC=3
mg/L). The rates of resistance to the other antibiotics were:
erythromycin, 42.3% (78/184); clindamycin, 36.4% (67/184);
tetracycline, 36.9% (68/184); and chloramphenicol, 1.6%
(3/184). In addition, 23.9% (44/184) were non-susceptible to
both penicillin and erythromycin. Non-PCV13 serotypes
accounted for 75.4% and 70.8% of the penicillin and
erythromycin non-susceptible isolates, respectively. The most
prevalent serotypes (6C, 24F, and 19A) included mainly
penicillin and/or erythromycin non-susceptible isolates, which
accounted for 89.4% of 6C, 75.0% of 24F, and 80.0% of 19A
isolates. A high rate of antibiotic non-susceptibility was also
present in serotypes 23B, 15A, 19F, 3, 14, 33F, and in NT
isolates (Figure 2).
Within each serotype, pneumococcal isolates were divided
into 4 categories: susceptible to penicillin and erythromycin
(green, PEN-S + ERY-S), non-susceptible to penicillin only
Figure 1.  Serotype distribution (in ranking order) of colonizing pneumococci collected from children.  
doi: 10.1371/journal.pone.0076309.g001
Table 2. Age-adjusted odds ratio of the association between the vaccination status of children and colonization by vaccine
serotypes (PCV7 and PCV13) and non-PCV13 serotypes.
 Total children PCV7 (N = 10)  PCV13 (N = 33)  non-PCV13 (N = 151)
 N N OR (95%CI) P  N OR (95%CI) P  N OR (95%CI) P
Vaccination status
unvaccinated 100 5 1    9 1    18 1   
PCV7 228 1 0.13 (0.02; 0.86) 0.034  5 0.34 (0.06; 2.07) 0.242  43 1.59 (0.96; 2.65) 0.073
PCV7/13+PCV13 170 4 0.30 (0.25; 0.37) <0.001  16 0.69 (0.66; 0.72) <0.001  69 1.90 (1.40; 2.57) <0.001
partially vaccinated 33 0 -    0 -    10 1.99 (1.97; 2.01) <0.001
unknown 40      3     11    
doi: 10.1371/journal.pone.0076309.t002
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(red, PEN-R), non-susceptible to erythromycin only (yellow,
ERY-R), and non-susceptible to penicillin and erythromycin
(striped, PEN-R + ERY-R).
The 93 isolates that were non-susceptible to penicillin and/or
erythromycin were genotyped. A complete MLST profile was
obtained for 54 isolates, while a partial MLST profile was used
for 39 isolates to infer the ST [21]. In total, 47 STs were
detected, clustered in 20 CCs and 2 singleton groups (Table 4).
The most abundant CC was CC156, which included 7 STs
clustered in different genetic lineages [22] and multiple
serotypes (6B, 6C, 14, 19F, 23B, and 24F). The second most
abundant CC was CC315, which included PMEN clone
Poland6B-20/ST315 and comprised only serotype 6C isolates,
followed by CC230, which included Denmark14-32/ST230 and
was composed of serotypes 19A and 24F. The non-susceptible
NT isolates belonged to CC344, which included NorwayNT-42/
ST344. Both the fully penicillin resistant isolate (MIC= 3 mg/L)
and the ceftriaxone-resistant isolate (MIC= 3 mg/L) were
serotype 19A and belonged to ST320/CC320, related to
Taiwan19F-14/ST236 (Table 4). The other isolates showing high
penicillin resistance (MIC> 1 mg/L) belonged mainly to CC230
and CC156. Among the most common serotypes, 6C (5 STs,
grouped in 4 different CCs and 1 Singleton group) and 19A (7
STs grouped in 3 different CCs) showed high genetic diversity.
Discussion
Surveillance of pneumococcal carriage is a good method for
monitoring the impact of pneumococcal conjugate vaccines at
the population level [2]. This study evaluated circulating
pneumococci among young Italian children at the end of PCV7
use and the beginning of PCV13. Two Italian cities were
selected for this study; although, the participants were
considered a single homogeneous population since there was
no significant demographic difference between the two groups.
Table 3. Serotype distribution in ranking order.
Serotype Total  Bologna  Milan
 Ranking order No. isolates % Cumulative %  Ranking order No. isolates %  Ranking order No. isolates %
6C 1 19 10.3 10.3  1 11 11.8  1 8 8.7
24F 2 16 8.6 19.0  2 10 10.7  3 6 6.5
19A 3 15 8.1 27.1  3 9 9.6  3 6 6.5
11A 4 13 7.0 34.2  5 6 6.4  2 7 7.6
15B 4 13 7.0 41.3  5 6 6.4  2 7 7.6
23B 5 11 5.9 47.2  8 3 3.2  1 8 8.7
23A 6 10 5.4 52.7  6 5 5.3  4 5 5.4
NT 6 10 5.4 58.1  6 5 5.3  4 5 5.4
10A 7 8 4.3 62.5  4 8 8.6  - 0 0
35B 8 7 3.8 66.3  7 4 4.3  5 3 3.2
15A 9 6 3.2 69.5  8 3 3.2  5 3 3.2
19F 9 6 3.2 72.8  10 1 1.0  4 5 5.4
35F 9 6 3.2 76.0  10 1 1.0  4 5 5.4
15C 10 5 2.7 78.8  9 2 2.1  5 3 3.2
21 10 5 2.7 81.5  9 2 2.1  5 3 3.2
38 10 5 2.7 84.2  8 3 3.2  6 2 2.1
3 11 3 1.6 85.8  10 1 1.0  6 2 2.1
22F 11 3 1.6 87.5  10 1 1.0  6 2 2.1
31 11 3 1.6 89.1  9 2 2.1  7 1 1.0
6A 12 2 1.0 90.2  10 1 1.0  7 1 1.0
7F 12 2 1.0 91.3  9 2 2.1  - 0 0
8 12 2 1.0 92.3  9 2 2.1  - 0 0
14 12 2 1.0 93.4  10 1 1.0  7 1 1.0
16 12 2 1.0 94.5  10 1 1.0  7 1 1.0
29 12 2 1.0 95.6  - 0 0  6 2 2.1
33F 12 2 1.0 96.7  10 1 1.0  7 1 1.0
1 13 1 0.5 97.2  - 0 0  7 1 1.0
6B 13 1 0.5 97.8  - 0 0  7 1 1.0
12F 13 1 0.5 98.3  10 1 1.0  - 0 0
18C 13 1 0.5 98.9  - 0 0  7 1 1.0
20 13 1 0.5 99.4  10 1 1.0  - 0 0
34 13 1 0.5 100  - 0 0  7 1 1.0
All  184     93    91  
doi: 10.1371/journal.pone.0076309.t003
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In studies conducted in other countries, the pneumococcal
carriage rate in young children ranged from 2% to more than
80%, depending on the geographical areas, the socio-
economic conditions, and the methods used in the carriage
study, including the sampling site (nasopharynx versus
oropharynx) [4,9-12,19,23]. Both cultural and molecular
methods have been used for carriage studies. Molecular
methods, based on pneumococcal DNA detection, are able to
identify a higher number of carriers than traditional cultural
methods and can allow identification of multiple colonizing
serotypes [24,25]. However, cultural methods provide viable
bacteria that can be submitted for further characterization,
including antimicrobial susceptibility testing.
In our study, the pneumococcal carriage rate was 32.9%,
which is consistent with the rates reported in recent studies
using cultural methods [12,23]. Our results showed that
children aged 6-35 months had the highest potential risk of
colonization by pneumococcus. As expected, day-care
attendance and the presence of young siblings were
associated with an increased prevalence of carriage; although,
multivariate analysis showed these were not independent
factors. Unexpectedly, we found a decreased risk of carriage in
association with the presence of at least one smoking parent.
This finding is in contrast to the results of several studies that
reported passive smoking represents a risk factor for
pneumococcal disease and carriage [26-28]. A more detailed
analysis of the children from Milan revealed the risk of
pneumococcal colonization increased if the mother was the
smoking parent. We do not have an explanation for this
association and presume other factors that we have not
investigated play a role.
The proportion of children completing the recommended
vaccinations for their age with PCV7, PCV13, or a combination
of the two was 74.9%. There was a difference in the
immunization rates between Bologna and Milan (97.8% versus
57.5%), which likely reflects the different vaccination strategies
implemented in the two regions [13]; although, this difference
did not appear to influence the pneumococcal colonization rate
in this study.
A total of 31 different serotypes were found, with 7 (6C, 24F,
19A, 11A, 15B, 23B, and 23A) representing the majority of
those detected; in addition, 5.4% and 17.9% were PCV7 and
PCV13 serotypes, respectively. The low rate of PCV13
serotypes was expected since some (1, 3, 5, and 7F) are rarely
found in the nasopharynx, irrespective of vaccination, likely
because they colonize only for a short period of time and at a
Figure 2.  Serotype distribution of penicillin and/or erythromycin non-susceptible isolates.  
doi: 10.1371/journal.pone.0076309.g002
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Table 4. Genotypic and phenotypic characteristics of the 93
antibiotic-non susceptible S. pneumoniae isolates.
CCa (No.
isolates) STsb (No. isolates)
Serotype (No.
isolates)
Resistance patternsc
(No. isolates)
156 (16) 2372 (4), 7121 (3) 23B (7) P (7)
 8511 (1) 19F (1) PT (1)
 162 (4) 24F (4) PECT (1), ECT (2), EC(1)
 143 (2) 14 (2) PCxECT (1), PCxEC (1)
 138 (1) 6C (1) ECT (1)
 469 (1) 6B (1) ECT (1)
315 (13) 386 (13) 6C (13) PECT (11), ECT (2)
230 (12) 230 (8) 24F (8) PECT (8)
 276 (1), 2013 (1),2674 (1), 9037 (1) 19A (4) PCxECT (2), PT (2)
344 (8) 344 (5), 3097 (1),4149 (1), 8448 (1) NT (8)
PCxECT (1), PECT (5),
PET (1), PCx (1)
199 (6) 416 (5), 2343 (1) 19A (6) ECT (5), EC (1)
63 (6)
63 (1), 374 (1),
2613 (1), 8512 (1),
8872 (1)
15A (5) PECT (1), PEC (1), PET(1), ECT (1), ET (1)
 2543 (1) 10A (1) ECT (1)
193 (6) 179 (4) 19F (4) PECT (4)
 193 (1) 15B (1) ECT (1)
 1877 (1) 21 (1) ET (1)
439 (3) 42 (1), 2404 (1),8449 (1) 23A (3) ECT (1), EC (1), P (1)
320 (3) 320 (2) 19A (2) PCxECT (2)d
 236 (1) 19F (1) PCxET (1)
180 (3) 180 (3) 3 (3) ECTCh (2), ECT (1)
Se (3) 1577 (3) 15B (3) ECT (3)
62 (2) 62 (2) 11A (2) ET (1), E (1)
717 (2) 717 (2) 33F (2) ECT (1), EC (1)
473 (2) 473 (1) 6A (1) PE (1)
 6759 (1) 6C (1) ECT (1)
395 (1) 1692 (1) 6C (1) EC (1)
Se (1) 8447 (1) 6C (1) PET (1)
393 (1) 3098 (1) 38 (1) P (1)
460 (1) 446 (1) 35F (1) P (1)
2991 (1) 2991 (1) 35F (1) ECT (1)
198 (1) 4346 (1) 35B (1) P (1)
1262 (1) 8450 (1) 15C (1) PET (1)
3548 (1) 1766 (1) 31 (1) E (1)
a Clonal complex (CC) and b Sequence type (ST) as defined using information
from the MLST website (http://spneumoniae.mlst.net); for 54 isolates ST was
determined using a complete allelic profile, while for 39 isolates ST was inferred by
2 MLST alleles only (see Materials and Methods); c For penicillin and ceftriaxone
the patterns indicate non-susceptibility (penicillin MIC >0.06 mg/L and ceftriaxone
MIC>0.5 mg/L) unless otherwise stated; P: penicillin; Cx: ceftriaxone; E:
erythromycin; C: clindamycin; T: tetracycline; Ch: chloramphenicol; d The pattern
indicates one isolate fully resistant to penicillin and one isolate fully resistant to
ceftriaxone; e Singleton.
doi: 10.1371/journal.pone.0076309.t004
low density [2]. Conversely, non-PCV13 serotypes accounted
for 82.0% of the isolates, with 6C and 24F being the most
abundant.
This study was a cross-sectional analysis of nasopharyngeal
carriage in the Italian pediatric population; therefore, we could
not evaluate the changes in serotypes distribution following
vaccination. However, variations could be inferred from
carriage studies performed in Italy before PCV7
implementation, when more than 50% of the serotypes
detected in children were PCV7 ones [17,18]. The serotype
distribution found in this study is in accordance with several
carriage studies performed after PCV7 implementation in
different countries, and essentially reflects the effects of PCV7
vaccination [10-12,19,23,29-33]. The additional effect of
PCV13 could not be evaluated in this study due to the cross-
sectional design and the recent introduction of the vaccine.
PCV7 and PCV13 appeared to be protective against the
collective PCV7 and PCV13 serotypes, however protection
against individual vaccine serotypes could not be evaluated
due to the low number of isolates. In time, the impact of PCV13
on the pneumococcal reservoir will become more evident, and
will likely lead to a decline in serotype 19A, which was still
prominent in our study. Future studies can also monitor the
effect of PCV13 on serotype 6C, which was most common in
our study. Cross-reaction between serotype 6A and 6C has
been demonstrated in vitro [34] and cross-protection has been
shown in a clinical study in France, which reported a decrease
in serotype 6C nasopharyngeal carriage in children with acute
otitis media who had received at least 1 dose of PCV13 [35].
Serotype 6C was circulating in the pre-vaccine era in many
parts of the world [36-38]; although, there was an increase in
this serotype after PCV7 implementation, both in carriage
[39,40] and IPD [41,42]. A retrospective analysis of isolates
from a carriage study performed in Rome in 1999 [18] did not
identify any serotype 6C (unpublished data); while, 6C was the
most common serotype in our study. Genotyping confirmed
there is remarkable genetic heterogeneity of this serotype [36];
although, the majority of the isolates belonged to CC315/
ST386, a colonizing clone with multidrug resistance.
The high prevalence of serotype 24F among Italian children
is not surprising since this serotype was circulating in our
country and a cause of IPD prior to PCV7 [43], and increased
significantly after vaccine use [44]. This serotype also
increased after PCV7 was introduced in other European
countries both in carriage [10,11] and IPD [45]. In our study,
serotype 24F was mainly associated with the multidrug
resistant CC230, which also included serotype 19A. There was
also an increase in the incidence of serotype 19A worldwide,
both in IPD [21,46-48] and carriage [9,11], which was at least
partly due to serotype replacement after implementation of
PCV7. In Italy, serotype 19A increased significantly in IPD
mainly due to the expansion of pre-existing clones, such as
ST416/CC199, related to Netherlands15B-37/ST199 [44]. This
same clone was predominant among serotype 19A isolates
from our study that were antibiotic resistant. Serotype 19A
isolates were also associated with CC320, related to
Taiwan19F-14/ST236, another multidrug resistant clone [46].
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Overall, half of the colonizing pneumococci were antibiotic
non-susceptible. With the exception of serotype 19A, most of
these isolates had non-PCV13 serotypes, such as 6C, 24F,
and 15A. Although only one isolate had a penicillin MIC >2
mg/L and was considered fully resistant to penicillin, the rate of
penicillin non-susceptibility was significantly higher than that
reported for IPD isolates in Italy (31% versus 14%) [49].
Similarly, the rate of erythromycin resistance was higher than
that found in clinical isolates (41% versus 27%) [50]. Since
antibiotic use in the period preceding enrollment was not
investigated, we could not evaluate if there was a correlation
between treatment and an increased prevalence of
antimicrobial-resistant pneumococci.
There are some limitations of this study. This was a cross-
sectional study of nasopharyngeal carriage; therefore, it is not
possible to evaluate changing trends in serotypes or antibiotic
resistance, but only to obtain a snapshot of the current
situation. In addition, colonization of multiple pneumococcal
isolates was not investigated; therefore, some serotypes may
have been underestimated. Multiple isolates have been
reported in 1.5-50% of carriers [20,23,24,51]; although, a
recent study in Portugal demonstrated a decrease in the rate of
co-colonization in PCV7-vaccinated children [25]. There was
also a limitation in the MLST protocol, as ST was inferred on
the basis of only 2 MLST alleles for a portion of the isolates.
Due to the recombination ability of S. pneumoniae, some
isolates had divergent alleles compared with the reference
isolate within the same serotype/antibiotic susceptibility group.
This could lead to some inaccurate ST allocation, although the
CC assignment should not be affected [21].
In conclusion, this study analyzed the pneumococci
colonizing healthy children one year after PCV13 was
introduced in Italy. It is important to continue to monitor vaccine
impact and coverage, using the baseline established here for
future comparisons of pneumococcal serotypes.
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